首页 > 最新文献

Biology of Blood and Marrow Transplantation最新文献

英文 中文
Masthead (Purpose and Scope) 报头(用途及范围)
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/S1083-8791(20)30703-5
{"title":"Masthead (Purpose and Scope)","authors":"","doi":"10.1016/S1083-8791(20)30703-5","DOIUrl":"https://doi.org/10.1016/S1083-8791(20)30703-5","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Page A1"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1083-8791(20)30703-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136815785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Mixed Chimerism on Myelofibrosis Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation 混合嵌合对异基因造血干细胞移植后骨髓纤维化结果的影响。
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/j.bbmt.2020.09.003
Samer A. Srour, Uday R. Popat
{"title":"Impact of Mixed Chimerism on Myelofibrosis Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation","authors":"Samer A. Srour, Uday R. Popat","doi":"10.1016/j.bbmt.2020.09.003","DOIUrl":"10.1016/j.bbmt.2020.09.003","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages e301-e302"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.09.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38397749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis 与嵌合抗原受体T细胞治疗相关的心血管事件:横断面FDA不良事件报告系统分析
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/j.bbmt.2020.08.036
Avirup Guha , Daniel Addison , Prantesh Jain , Jahir M. Gutierrez , Arjun Ghosh , Claire Roddie , Marcos de Lima , Sadeer Al-Kindi , Guilherme H. Oliveira

Chimeric antigen receptor (CAR) T cell therapy is approved in the United States for the treatment of acute lymphocytic leukemia and aggressive B cell lymphomas. Multiple cardiovascular adverse events (CVEs) associated with CAR-Ts have been observed in small studies, but no large-scale studies exist. Leveraging the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS), we identified all reported adverse events (AEs) associated with CAR-T therapy (tisagenlecleucel and axicabtagene ciloleucel) from 2017 to 2019. Reports with missing age and sex were excluded. CVEs were classified into arrhythmias, heart failure (HF), myocardial infarction (MI), and other CVEs. Logistic regression and hierarchical clustering were used to identify factors associated with CVEs. A total of 996 reported AEs were observed (39.1% associated with tisagenlecleucel and 60% with axicabtagene ciloleucel). Of all patients experiencing AEs, the median age was 54 (interquartile range, 21 to 65) years; 38.9% were females. In total, 19.7% (196) of all AEs reported to the FDA were CVEs. The most common CVEs were arrhythmia (77.6%), followed by HF (14.3%) and MI (0.5%). In adjusted analysis a positive association was observed between those presenting with CVE with neurotoxicity (odds ratio, 1.76; 95% confidence interval, 1.20 to 2.60; P = .004). Additionally, when both CVE and cytokine release syndrome (CRS) are present, neurotoxicity is the most common noncardiac AE, which clusters with them (Jaccard similarity: 73.1). The mortality rate was 21.1% overall but 30.1% for those reporting CVEs. In FAERS, reported CVEs with CAR-T are associated with high reported mortality. The development of either CRS or neurotoxicity should prompt vigilance for cardiovascular events.

嵌合抗原受体(CAR) T细胞疗法在美国被批准用于治疗急性淋巴细胞白血病和侵袭性B细胞淋巴瘤。与car - t相关的多种心血管不良事件(CVEs)已在小型研究中观察到,但没有大规模的研究存在。利用美国食品和药物管理局(FDA)不良事件报告系统(FAERS),我们确定了2017年至2019年与CAR-T治疗(tisagenlecleucel和axicabtagene ciloleucel)相关的所有报告的不良事件(ae)。年龄和性别缺失的报告被排除在外。cve分为心律失常、心力衰竭(HF)、心肌梗死(MI)和其他cve。采用逻辑回归和分层聚类来确定与cve相关的因素。共观察到996例报告的ae(39.1%与tisagenlecleel相关,60%与axicabtagene ciloleel相关)。在所有经历ae的患者中,中位年龄为54岁(四分位数范围为21至65岁);38.9%为女性。向FDA报告的所有ae中,19.7%(196例)为cve。最常见的cve是心律失常(77.6%),其次是HF(14.3%)和MI(0.5%)。校正分析显示,CVE患者与神经毒性呈正相关(优势比为1.76;95%置信区间为1.20 ~ 2.60;P = 04)。此外,当CVE和细胞因子释放综合征(CRS)同时存在时,神经毒性是最常见的非心脏AE,与它们聚集在一起(Jaccard相似度:73.1)。总体死亡率为21.1%,但报告cve的死亡率为30.1%。在FAERS中,CAR-T合并cve的报道与高死亡率相关。CRS或神经毒性的发生应引起对心血管事件的警惕。
{"title":"Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis","authors":"Avirup Guha ,&nbsp;Daniel Addison ,&nbsp;Prantesh Jain ,&nbsp;Jahir M. Gutierrez ,&nbsp;Arjun Ghosh ,&nbsp;Claire Roddie ,&nbsp;Marcos de Lima ,&nbsp;Sadeer Al-Kindi ,&nbsp;Guilherme H. Oliveira","doi":"10.1016/j.bbmt.2020.08.036","DOIUrl":"10.1016/j.bbmt.2020.08.036","url":null,"abstract":"<div><p>Chimeric antigen receptor (CAR) T cell therapy is approved in the United States for the treatment of acute lymphocytic leukemia and aggressive B cell lymphomas. Multiple cardiovascular adverse events (CVEs) associated with CAR-Ts have been observed in small studies, but no large-scale studies exist. Leveraging the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS), we identified all reported adverse events (AEs) associated with CAR-T therapy (tisagenlecleucel and axicabtagene ciloleucel) from 2017 to 2019. Reports with missing age and sex were excluded. CVEs were classified into arrhythmias, heart failure (HF), myocardial infarction (MI), and other CVEs. Logistic regression and hierarchical clustering were used to identify factors associated with CVEs. A total of 996 reported AEs were observed (39.1% associated with tisagenlecleucel and 60% with axicabtagene ciloleucel). Of all patients experiencing AEs, the median age was 54 (interquartile range, 21 to 65) years; 38.9% were females. In total, 19.7% (196) of all AEs reported to the FDA were CVEs. The most common CVEs were arrhythmia (77.6%), followed by HF (14.3%) and MI (0.5%). In adjusted analysis a positive association was observed between those presenting with CVE with neurotoxicity (odds ratio, 1.76; 95% confidence interval, 1.20 to 2.60; <em>P</em> = .004). Additionally, when both CVE and cytokine release syndrome (CRS) are present, neurotoxicity is the most common noncardiac AE, which clusters with them (Jaccard similarity: 73.1). The mortality rate was 21.1% overall but 30.1% for those reporting CVEs. In FAERS, reported CVEs with CAR-T are associated with high reported mortality. The development of either CRS or neurotoxicity should prompt vigilance for cardiovascular events.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2211-2216"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38414129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
Improving Hematopoietic Stem Cell Transplant in the Elderly: Can We Finally Start to Impact Nonrelapse Mortality? 改善老年人造血干细胞移植:我们能最终开始影响非复发死亡率吗?
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/j.bbmt.2020.10.013
Thomas G. Knight
{"title":"Improving Hematopoietic Stem Cell Transplant in the Elderly: Can We Finally Start to Impact Nonrelapse Mortality?","authors":"Thomas G. Knight","doi":"10.1016/j.bbmt.2020.10.013","DOIUrl":"10.1016/j.bbmt.2020.10.013","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages e303-e304"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.10.013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38592213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis 早期混合淋巴供体/宿主嵌合与原发性或继发性骨髓纤维化患者移植预后改善相关
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/j.bbmt.2020.07.013
H. Joachim Deeg , Rachel B. Salit , Tim Monahan , Gary Schoch , Chris McFarland , Bart L. Scott , Barry E. Storer

We investigated risk factors for the development of mixed chimerism in 131 patients who underwent transplantation for myelofibrosis and determined the impact of lymphoid (CD3+) and myeloid (CD33+) chimerism on transplant outcome. Disease risk included DIPSS plus categories low to high. The median patient age was 58 years. Patients were conditioned with high-intensity (myeloablative) or low/reduced-intensity (nonmyeloablative) regimens and received a transplant from a related or unrelated donor. Mixed CD3+ chimerism was observed earlier after HCT, whereas CD33+ chimerism occurred later. Mixed chimerism was more frequent with low-intensity regimens than with high- intensity regimens. Mixed CD3+ chimerism did not lead to graft failure and was associated with a reduced incidence of acute GVHD and improved overall survival (OS) and relapse-free survival, whereas mixed CD33+ chimerism was associated with an increased incidence of relapse and reduced OS and relapse-free survival, independent of the CD34+ cell dose transplanted. Thus, mixed CD3+ chimerism in patients with myelofibrosis had a favorable impact on transplantation outcome and does not require therapeutic interventions.

我们研究了131例因骨髓纤维化而接受移植的患者发生混合嵌合的危险因素,并确定了淋巴细胞(CD3+)和骨髓细胞(CD33+)嵌合对移植结果的影响。疾病风险包括DIPSS加上从低到高的类别。患者年龄中位数为58岁。患者接受高强度(清髓)或低/降低强度(非清髓)方案,并接受来自亲属或非亲属供体的移植。HCT后CD3+嵌合较早,CD33+嵌合较晚。混合嵌合在低强度治疗组比高强度治疗组更常见。混合CD3+嵌合不会导致移植物衰竭,并与急性GVHD发生率降低、总生存期(OS)和无复发生存期改善相关,而混合CD33+嵌合与复发发生率增加、总生存期降低和无复发生存期相关,与移植的CD34+细胞剂量无关。因此,骨髓纤维化患者的混合CD3+嵌合对移植结果有良好的影响,不需要治疗干预。
{"title":"Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis","authors":"H. Joachim Deeg ,&nbsp;Rachel B. Salit ,&nbsp;Tim Monahan ,&nbsp;Gary Schoch ,&nbsp;Chris McFarland ,&nbsp;Bart L. Scott ,&nbsp;Barry E. Storer","doi":"10.1016/j.bbmt.2020.07.013","DOIUrl":"10.1016/j.bbmt.2020.07.013","url":null,"abstract":"<div><p>We investigated risk factors for the development of mixed chimerism in 131 patients who underwent transplantation for myelofibrosis and determined the impact of lymphoid (CD3+) and myeloid (CD33+) chimerism on transplant outcome. Disease risk included DIPSS plus categories low to high. The median patient age was 58 years. Patients were conditioned with high-intensity (myeloablative) or low/reduced-intensity (nonmyeloablative) regimens and received a transplant from a related or unrelated donor. Mixed CD3<sup>+</sup> chimerism was observed earlier after HCT, whereas CD33<sup>+</sup> chimerism occurred later. Mixed chimerism was more frequent with low-intensity regimens than with high- intensity regimens. Mixed CD3<sup>+</sup> chimerism did not lead to graft failure and was associated with a reduced incidence of acute GVHD and improved overall survival (OS) and relapse-free survival, whereas mixed CD33<sup>+</sup> chimerism was associated with an increased incidence of relapse and reduced OS and relapse-free survival, independent of the CD34<sup>+</sup> cell dose transplanted. Thus, mixed CD3<sup>+</sup> chimerism in patients with myelofibrosis had a favorable impact on transplantation outcome and does not require therapeutic interventions.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2197-2203"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38175716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience 自体干细胞移植巩固原发性中枢神经系统淋巴瘤的结果:梅奥诊所的经验
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/j.bbmt.2020.08.012
Arushi Khurana , Ivana N. Micallef , Betsy R. LaPlant , Brian Patrick O’Neill , Thomas M. Habermann , Stephen M. Ansell , David J. Inwards , Luis F. Porrata , Jonas Paludo , J.C. Villasboas Bisneto , Patrick B. Johnston

A paucity of randomized phase III clinical trials in primary central nervous system lymphoma (PCNSL) has resulted in no uniform consensus on the optimal strategy for consolidation and conditioning regimens for autologous stem cell transplant (ASCT). The past 2 decades have witnessed a preference for thiotepa (TT)-based conditioning regimens due to superior central nervous system penetration. We retrospectively evaluated outcomes of patients with PCNSL who underwent ASCT at Mayo Clinic, Rochester over the past 2 decades, and the impact of TT-based conditioning regimens. Fifty-six patients underwent transplant for PCNSL, with 25 and 31 patients receiving BEAM (non-thiotepa) and carmustine (BCNU)/TT-based conditioning, respectively. All patients received high-dose methotrexate-based induction therapy. While the BCNU/TT group had higher risk disease features such as high International Extranodal Lymphoma Study Group prognostic score, elevated cerebrospinal fluid protein, and older patient population, there was no significant difference at 2 years post-transplant in progression-free survival (BEAM 68.0% [46.1% to 82.5%] versus BCNU/TT, 65.5% [45.2% to 79.8%], P = .99) or overall survival (OS) (84.0% [62.8% to 93.7%] in the BEAM group versus 81.6% [61.3% to 91.9%] in the BCNU/TT group, P = .95). Disease response status before transplant significantly affected the outcomes as those in complete remission had an OS at 2 years post-transplant of 94.7% (68.1% to 99.2%) in the BEAM group and 90.5% (67.0% to 97.5%) in the BCNU/TT group compared with those in partial response, 57.1% (17.2% to 83.7%) in BCNU/TT group and 50.0% (11.1% to 80.4%) in the BEAM group, respectively (P < .0001). Our retrospective cohort adds to the currently available literature and identifies the disease status before transplant as a significant factor affecting survival.

原发性中枢神经系统淋巴瘤(PCNSL)的随机III期临床试验的缺乏导致对自体干细胞移植(ASCT)巩固和调理方案的最佳策略没有统一的共识。在过去的20年里,由于具有优越的中枢神经系统穿透性,人们更倾向于使用硫替帕(TT)为基础的调理方案。我们回顾性评估了过去20年来在罗切斯特梅奥诊所接受ASCT的PCNSL患者的预后,以及基于tt的调理方案的影响。56例患者接受了PCNSL移植,其中25例和31例患者分别接受了BEAM(非硫替帕)和卡莫司汀(BCNU)/ tt治疗。所有患者均接受大剂量甲氨蝶呤诱导治疗。虽然BCNU/TT组具有较高的疾病风险特征,如国际结外淋巴瘤研究组预后评分高、脑脊液蛋白升高和患者年龄较大,但移植后2年无进展生存率(BEAM为68.0%[46.1%至82.5%]与BCNU/TT相比,65.5%[45.2%至79.8%],P = 0.99)或总生存率(OS) (BEAM组为84.0%[62.8%至93.7%]与BCNU/TT组为81.6%[61.3%至91.9%])无显著差异。p = .95)。移植前疾病反应状态显著影响预后,移植后2年完全缓解患者的OS在BEAM组为94.7% (68.1% ~ 99.2%),BCNU/TT组为90.5%(67.0% ~ 97.5%),而部分缓解组为57.1% (17.2% ~ 83.7%),BEAM组为50.0% (11.1% ~ 80.4%)(P <。)。我们的回顾性队列增加了现有文献,并确定移植前的疾病状态是影响生存的重要因素。
{"title":"Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience","authors":"Arushi Khurana ,&nbsp;Ivana N. Micallef ,&nbsp;Betsy R. LaPlant ,&nbsp;Brian Patrick O’Neill ,&nbsp;Thomas M. Habermann ,&nbsp;Stephen M. Ansell ,&nbsp;David J. Inwards ,&nbsp;Luis F. Porrata ,&nbsp;Jonas Paludo ,&nbsp;J.C. Villasboas Bisneto ,&nbsp;Patrick B. Johnston","doi":"10.1016/j.bbmt.2020.08.012","DOIUrl":"10.1016/j.bbmt.2020.08.012","url":null,"abstract":"<div><p>A paucity of randomized phase III clinical trials in primary central nervous system lymphoma (PCNSL) has resulted in no uniform consensus on the optimal strategy for consolidation and conditioning regimens for autologous stem cell transplant (ASCT). The past 2 decades have witnessed a preference for thiotepa (TT)-based conditioning regimens due to superior central nervous system penetration. We retrospectively evaluated outcomes of patients with PCNSL who underwent ASCT at Mayo Clinic, Rochester over the past 2 decades, and the impact of TT-based conditioning regimens. Fifty-six patients underwent transplant for PCNSL, with 25 and 31 patients receiving BEAM (non-thiotepa) and carmustine (BCNU)/TT-based conditioning, respectively. All patients received high-dose methotrexate-based induction therapy. While the BCNU/TT group had higher risk disease features such as high International Extranodal Lymphoma Study Group prognostic score, elevated cerebrospinal fluid protein, and older patient population, there was no significant difference at 2 years post-transplant in progression-free survival (BEAM 68.0% [46.1% to 82.5%] versus BCNU/TT, 65.5% [45.2% to 79.8%], <em>P</em> = .99) or overall survival (OS) (84.0% [62.8% to 93.7%] in the BEAM group versus 81.6% [61.3% to 91.9%] in the BCNU/TT group, <em>P</em> = .95). Disease response status before transplant significantly affected the outcomes as those in complete remission had an OS at 2 years post-transplant of 94.7% (68.1% to 99.2%) in the BEAM group and 90.5% (67.0% to 97.5%) in the BCNU/TT group compared with those in partial response, 57.1% (17.2% to 83.7%) in BCNU/TT group and 50.0% (11.1% to 80.4%) in the BEAM group, respectively (<em>P</em> &lt; .0001). Our retrospective cohort adds to the currently available literature and identifies the disease status before transplant as a significant factor affecting survival.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2217-2222"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38282143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma 来那度胺维持治疗复发或难治性经典霍奇金淋巴瘤自体移植后的初步研究
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/j.bbmt.2020.08.017
Lauren Shea , Marcus P. Watkins , Fei Wan , Amanda F. Cashen , Nina D. Wagner-Johnston , Meagan A. Jacoby , Camille N. Abboud , John F. Dipersio , David D. Hurd , Samantha M. Jaglowski , Nancy L. Bartlett , Todd A. Fehniger

For patients with relapsed or refractory classical Hodgkin lymphoma (cHL), salvage chemotherapy followed by consolidation with autologous stem cell transplant (ASCT) remains the standard of care. Even with this aggressive treatment strategy, 5-year progression-free survival is ≤50%, and there remains interest in maintenance strategies to improve long-term disease-free survival. Lenalidomide is an immunomodulatory agent with demonstrated activity in multiple subtypes of lymphoma including cHL, and has also been shown to improve both progression-free and overall survival as maintenance therapy after ASCT in multiple myeloma. This multicenter study evaluated maintenance lenalidomide after ASCT for patients with cHL. Patients were enrolled 60 to 90 days post-transplant and received oral lenalidomide on days 1 to 28 of 28-day cycles for a maximum of 18 cycles. Lenalidomide was started at 15 mg daily and increased to maximum of 25 mg daily if tolerated. The primary objective of this study was to assess the feasibility of this regimen, with a goal <30% rate of discontinuation at or before cycle 12 for drug-related reasons. Twenty-seven patients were enrolled and 26 received at least 1 dose of lenalidomide. With a median follow-up of 51.3 months (range, 12.2 to 76.2 months), 23 of 26 patients were alive. Median event-free survival was 9.4 months and median progression-free survival had not been reached, with 17 of 26 patients (65.4%) remaining in remission at last follow-up. Excluding 4 patients who discontinued therapy for progression and 2 who discontinued due to noncompliance, the discontinuation rate at or before cycle 12 was 52%. Treatment was complicated by a high frequency of hematologic adverse events, with 15 patients (58%) experiencing grade 3 to 4 hematologic toxicity and 5 (19%) experiencing grade 4 hematologic toxicity. We conclude that the regimen of maintenance lenalidomide explored in this study is not feasible for patients with cHL immediately following ASCT. An alternative lenalidomide dose or schedule may be better tolerated following ASCT for patients with relapsed or refractory cHL.

对于复发或难治性经典霍奇金淋巴瘤(cHL)患者,补救性化疗后自体干细胞移植(ASCT)巩固仍然是标准的治疗方法。即使采用这种积极的治疗策略,5年无进展生存率仍≤50%,并且仍有兴趣采用维持策略来提高长期无病生存率。来那度胺是一种免疫调节剂,在包括cHL在内的多种淋巴瘤亚型中具有活性,并且也被证明可以改善多发性骨髓瘤ASCT后的无进展和总生存期。这项多中心研究评估了来那度胺对cHL患者ASCT后的维持作用。患者在移植后60至90天入组,在28天周期的第1至28天口服来那度胺,最多18个周期。来那度胺起始剂量为每日15毫克,如果耐受,则增加至每日最大剂量25毫克。本研究的主要目的是评估该方案的可行性,目标是在第12周期或之前因药物相关原因停药的比率为30%。27例患者入组,其中26例接受了至少1剂来那度胺治疗。中位随访51.3个月(范围12.2 - 76.2个月),26例患者中有23例存活。中位无事件生存期为9.4个月,中位无进展生存期未达到,26例患者中有17例(65.4%)在最后随访时仍处于缓解期。排除4名因进展而停药的患者和2名因不依从性而停药的患者,在第12周期或之前的停药率为52%。治疗伴有高频率的血液学不良事件,15名患者(58%)出现3至4级血液学毒性,5名患者(19%)出现4级血液学毒性。我们的结论是,本研究中探索的来那度胺维持方案对于ASCT后立即发生cHL的患者是不可行的。对于复发或难治性cHL患者,ASCT后替代来那度胺剂量或方案可能耐受性更好。
{"title":"A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma","authors":"Lauren Shea ,&nbsp;Marcus P. Watkins ,&nbsp;Fei Wan ,&nbsp;Amanda F. Cashen ,&nbsp;Nina D. Wagner-Johnston ,&nbsp;Meagan A. Jacoby ,&nbsp;Camille N. Abboud ,&nbsp;John F. Dipersio ,&nbsp;David D. Hurd ,&nbsp;Samantha M. Jaglowski ,&nbsp;Nancy L. Bartlett ,&nbsp;Todd A. Fehniger","doi":"10.1016/j.bbmt.2020.08.017","DOIUrl":"10.1016/j.bbmt.2020.08.017","url":null,"abstract":"<div><p>For patients with relapsed or refractory classical Hodgkin lymphoma (cHL), salvage chemotherapy followed by consolidation with autologous stem cell transplant (ASCT) remains the standard of care. Even with this aggressive treatment strategy, 5-year progression-free survival is ≤50%, and there remains interest in maintenance strategies to improve long-term disease-free survival. Lenalidomide is an immunomodulatory agent with demonstrated activity in multiple subtypes of lymphoma including cHL, and has also been shown to improve both progression-free and overall survival as maintenance therapy after ASCT in multiple myeloma. This multicenter study evaluated maintenance lenalidomide after ASCT for patients with cHL. Patients were enrolled 60 to 90 days post-transplant and received oral lenalidomide on days 1 to 28 of 28-day cycles for a maximum of 18 cycles. Lenalidomide was started at 15 mg daily and increased to maximum of 25 mg daily if tolerated. The primary objective of this study was to assess the feasibility of this regimen, with a goal &lt;30% rate of discontinuation at or before cycle 12 for drug-related reasons. Twenty-seven patients were enrolled and 26 received at least 1 dose of lenalidomide. With a median follow-up of 51.3 months (range, 12.2 to 76.2 months), 23 of 26 patients were alive. Median event-free survival was 9.4 months and median progression-free survival had not been reached, with 17 of 26 patients (65.4%) remaining in remission at last follow-up. Excluding 4 patients who discontinued therapy for progression and 2 who discontinued due to noncompliance, the discontinuation rate at or before cycle 12 was 52%. Treatment was complicated by a high frequency of hematologic adverse events, with 15 patients (58%) experiencing grade 3 to 4 hematologic toxicity and 5 (19%) experiencing grade 4 hematologic toxicity. We conclude that the regimen of maintenance lenalidomide explored in this study is not feasible for patients with cHL immediately following ASCT. An alternative lenalidomide dose or schedule may be better tolerated following ASCT for patients with relapsed or refractory cHL.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2223-2228"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38292464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Fanconi Anemia: Improving Outcomes with Improved Supportive Care in India 单倍体干细胞移植与移植后环磷酰胺治疗范可尼贫血:改善印度支持治疗的结果
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/j.bbmt.2020.08.019
Ramya Uppuluri , Venkateswaran Vellaichamy Swaminathan , Kesavan Melarcode Ramanan , Satishkumar Meena , Harika Varla , Balasubramaniam Ramakrishnan , Indira Jayakumar , Revathi Raj

Fanconi anemia is the most common inherited bone marrow failure syndrome, and hematopoietic stem cell transplantation (HSCT) is the only curative option. Post-transplant cyclophosphamide (PTCy) is challenging in this group of children, given their increased sensitivity to chemotherapy. We performed a retrospective analysis of the data on children diagnosed with Fanconi anemia who underwent a haploidentical HSCT with PTCy from January 2014 to December 2019. Nineteen children (male/female, 0.75:1) underwent 21 haplo-HSCTs with PTCy. Fludarabine, low-dose cyclophosphamide, and 200 centi-gray total body irradiation were included in the conditioning regimen with 25 mg/kg PTCy on days +3 and +4. Haplo-graft was from a sibling in 38% and father in 57% of transplants. The source of stem cells was peripheral blood stem cells in 81% and bone marrow in 19% of transplants, with a median CD34 dose of 5.0 × 106/kg. We documented engraftment in 84% and primary graft failure in 10% of transplants. N-acetylcysteine (NAC) was infused concomitantly during cyclophosphamide in 13 children. Grade 2 and 3 mucositis was lower among those who received NAC as compared to those who did not (30% and 15% versus 33% and 50%), while transaminitis was higher among those who did not receive the infusion. The incidence of acute graft-versus-host disease (GVHD) was 68%, and 81% of these were steroid responsive (grade I/II). We documented chronic GVHD in 25% children, predominantly involving the skin and mouth, which responded to low-dose steroids and ruxolitinib. Serum ferritin was monitored twice weekly as a surrogate marker for cytokine release syndrome due to nonavailability of IL-6 levels. A 1- or 2-log increase in the titers of ferritin associated with clinical features guided the early addition of steroids in the periengraftment period. The mean survival was found to be less among those with high serum ferritin (>10,000 ng/dL) in the periengraftment period as compared to those with ferritin <10,000 ng/dL (mean survival of 25 ± 10 months versus 50 ± 6 months, respectively). The overall survival in our cohort was 68.4%, with a mean survival time of 41.5 months (95% confidence interval, 29.3 to 53.8 months), with a statistically significant correlation between inferior outcome and having received over 15 transfusions before HSCT (P = .01). PTCy can be considered a viable option in children with Fanconi anemia, particularly in resource-limited settings given the high costs of HSCTs. Focused interventions in this subset of children help improve survival outcomes. Early identification of cytokine release syndrome and risk-adapted steroid therapy during engraftment helps prevent mortality. The concomitant use of NAC during cyclophosphamide infusion helps reduce oxygen free radical related tissue damage and regimen-related toxicity.

范可尼贫血是最常见的遗传性骨髓衰竭综合征,造血干细胞移植(HSCT)是唯一的治疗选择。移植后环磷酰胺(PTCy)在这组儿童中具有挑战性,因为他们对化疗的敏感性增加。我们对2014年1月至2019年12月期间接受PTCy单倍同型HSCT治疗的诊断为范可尼贫血的儿童进行了回顾性分析。19名儿童(男/女,0.75:1)接受了21例含PTCy的单倍hsct。氟达拉滨、低剂量环磷酰胺和200厘灰全身照射在+3和+4天以25 mg/kg PTCy进行调节。单倍体移植来自兄弟姐妹的占38%,来自父亲的占57%。干细胞来源为外周血干细胞(81%)和骨髓(19%),中位CD34剂量为5.0 × 106/kg。我们记录了84%的移植成功,10%的移植失败。13例患儿在环磷酰胺治疗期间同时输注n -乙酰半胱氨酸(NAC)。2级和3级粘膜炎在接受NAC的患者中比未接受NAC的患者低(30%和15%对33%和50%),而在未接受NAC输注的患者中,转氨炎的发生率更高。急性移植物抗宿主病(GVHD)的发生率为68%,其中81%对类固醇有反应(I/II级)。我们记录了25%的儿童慢性GVHD,主要涉及皮肤和口腔,对低剂量类固醇和鲁索利替尼有反应。每周监测两次血清铁蛋白,作为细胞因子释放综合征的替代标志物,因为无法获得IL-6水平。与临床特征相关的铁蛋白滴度的1-或2-log的增加指导了在植入期早期添加类固醇。与铁蛋白含量为1万ng/dL的患者相比,高血清铁蛋白(1万ng/dL)患者在移植围期的平均生存时间较短(平均生存时间分别为25±10个月和50±6个月)。我们队列的总生存率为68.4%,平均生存时间为41.5个月(95%可信区间为29.3 ~ 53.8个月),不良预后与HSCT前输血超过15次有统计学意义(P = 0.01)。PTCy可以被认为是范可尼贫血儿童的可行选择,特别是在资源有限的环境中,鉴于hsct的高成本。对这部分儿童进行重点干预有助于改善生存结果。在植入过程中早期识别细胞因子释放综合征和适应风险的类固醇治疗有助于预防死亡。在环磷酰胺输注期间同时使用NAC有助于减少氧自由基相关的组织损伤和方案相关的毒性。
{"title":"Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Fanconi Anemia: Improving Outcomes with Improved Supportive Care in India","authors":"Ramya Uppuluri ,&nbsp;Venkateswaran Vellaichamy Swaminathan ,&nbsp;Kesavan Melarcode Ramanan ,&nbsp;Satishkumar Meena ,&nbsp;Harika Varla ,&nbsp;Balasubramaniam Ramakrishnan ,&nbsp;Indira Jayakumar ,&nbsp;Revathi Raj","doi":"10.1016/j.bbmt.2020.08.019","DOIUrl":"10.1016/j.bbmt.2020.08.019","url":null,"abstract":"<div><p>Fanconi anemia is the most common inherited bone marrow failure syndrome, and hematopoietic stem cell transplantation (HSCT) is the only curative option. Post-transplant cyclophosphamide (PTCy) is challenging in this group of children, given their increased sensitivity to chemotherapy. We performed a retrospective analysis of the data on children diagnosed with Fanconi anemia who underwent a haploidentical HSCT with PTCy from January 2014 to December 2019. Nineteen children (male/female, 0.75:1) underwent 21 haplo-HSCTs with PTCy. Fludarabine, low-dose cyclophosphamide, and 200 centi-gray total body irradiation were included in the conditioning regimen with 25 mg/kg PTCy on days +3 and +4. Haplo-graft was from a sibling in 38% and father in 57% of transplants. The source of stem cells was peripheral blood stem cells in 81% and bone marrow in 19% of transplants, with a median CD34 dose of 5.0 × 10<sup>6</sup>/kg. We documented engraftment in 84% and primary graft failure in 10% of transplants. <em>N</em>-acetylcysteine (NAC) was infused concomitantly during cyclophosphamide in 13 children. Grade 2 and 3 mucositis was lower among those who received NAC as compared to those who did not (30% and 15% versus 33% and 50%), while transaminitis was higher among those who did not receive the infusion. The incidence of acute graft-versus-host disease (GVHD) was 68%, and 81% of these were steroid responsive (grade I/II). We documented chronic GVHD in 25% children, predominantly involving the skin and mouth, which responded to low-dose steroids and ruxolitinib. Serum ferritin was monitored twice weekly as a surrogate marker for cytokine release syndrome due to nonavailability of IL-6 levels. A 1- or 2-log increase in the titers of ferritin associated with clinical features guided the early addition of steroids in the periengraftment period. The mean survival was found to be less among those with high serum ferritin (&gt;10,000 ng/dL) in the periengraftment period as compared to those with ferritin &lt;10,000 ng/dL (mean survival of 25 ± 10 months versus 50 ± 6 months, respectively). The overall survival in our cohort was 68.4%, with a mean survival time of 41.5 months (95% confidence interval, 29.3 to 53.8 months), with a statistically significant correlation between inferior outcome and having received over 15 transfusions before HSCT (<em>P</em> = .01). PTCy can be considered a viable option in children with Fanconi anemia, particularly in resource-limited settings given the high costs of HSCTs. Focused interventions in this subset of children help improve survival outcomes. Early identification of cytokine release syndrome and risk-adapted steroid therapy during engraftment helps prevent mortality. The concomitant use of NAC during cyclophosphamide infusion helps reduce oxygen free radical related tissue damage and regimen-related toxicity.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2292-2298"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38297955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Use of Potentially Inappropriate Medications in Older Allogeneic Hematopoietic Cell Transplantation Recipients 老年异基因造血细胞移植受者潜在不适当药物的使用
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/j.bbmt.2020.08.031
Divya Bhargava , Mukta Arora , Todd E. DeFor , Claudio G. Brunstein , Bharat Thyagarajan , Najla El Jurdi , Shernan G. Holtan , Armin Rashidi , Erica Warlick , Vidhyalakshmi Ramesh , John Rogosheske , Smita Bhatia , Daniel J. Weisdorf

The use of potentially inappropriate medications (PIMs) using Beers criteria and its impact on older allogeneic hematopoietic cell transplantation (HCT) recipients is not known. Here the use of any PIMs and their therapeutic classes in reduced-intensity conditioning allogeneic HCT recipients were compared between older (≥65 years; n = 114) and younger (40 to 64 years; n = 240) patients during their initial HCT admission, defined as the number of days that a patient received 1 or more PIMs between day -14 and day +28. Poisson regression was used to determine rate ratios (RRs) in the 2 groups. In the ≥65 years group, we evaluated the impact of PIMs on Common Terminology Criteria for Adverse Events (CTCAE) grade 3-4 toxicities within 100 days and on overall mortality within 1 year post-HCT. The rate of any PIM use was similar in the older and younger groups (RR, .98; 95% confidence interval [CI], .90 to 1.06; P = .65). In terms of PIM classes, the older group had a 48% higher rate of gastrointestinal (GI) medication use (RR, 1.48; 95% CI, 1.32 to 1.65; P < .01) and a 25% higher rate of genitourinary (GU) medication use (RR, 1.25; 95% CI, 1.02 to 1.53; P = .03). Compared with males, females had a 19% higher rate of central nervous system (CNS) medication use (RR, 1.19; 95% CI, 1.03 to 1.37; P = .02) and a 30% higher rate of benzodiazepine use (RR, 1.30; 95% CI. 1.09 to 1.54; P < .01). A high-risk HCT-CI was associated with a higher rate of use of any PIMs (RR, 1.13; 95% CI, 1.01 to 1.26; P = .02), CNS medications (RR, 1.26; 95% CI, 1.04 to 1.53; P = .02) and GU medications (RR, 1.46; 95% CI, 1.09 to 1.94; P = .01). Compared with matched sibling donor HCT recipients, umbilical cord blood transplantation recipients had higher rates of GI medication use (RR, 1.32; 95% CI, 1.14 to 1.53; P < .01) and anticholinergic medication use (RR, 1.30; 95% CI, 1.06 to 1.61; P = .01). In the ≥65 years group, increasing duration of narcotic use was associated with a 1.3-fold (95% CI, 1.0 to 1.7; P = .05) higher risk of overall mortality and a 1.6-fold (95% CI, 1.02 to 2.69) greater odds of CTCAE grade 3-4 toxicities (P = .04). Our data show that older recipients (≥65 years) were as likely as their younger counterparts to receive PIMs. Among older recipients, the use of PIMs, particularly narcotics, was associated with higher mortality and higher incidence of grade 3-4 toxicities. Identifying and reducing the use of PIMs in older HCT recipients may help decrease the burden of adverse events and associated health care costs.

使用Beers标准的潜在不适当药物(pim)及其对老年同种异体造血细胞移植(HCT)受者的影响尚不清楚。在本研究中,我们比较了年龄较大(≥65岁;N = 114)及以下(40 ~ 64岁;n = 240)患者在首次HCT入院期间,定义为患者在-14天至+28天之间接受1次或以上pim的天数。采用泊松回归确定两组间的发病率比(rr)。在≥65岁的组中,我们评估了PIMs对100天内不良事件通用术语标准(CTCAE) 3-4级毒性的影响以及对hct后1年内总死亡率的影响。老年组和年轻组的PIM使用率相似(RR, 0.98;95%置信区间[CI], 0.90 ~ 1.06;p = .65)。就PIM类别而言,老年组胃肠道(GI)用药率高出48% (RR, 1.48;95% CI, 1.32 ~ 1.65;P & lt;.01),泌尿生殖系统(GU)药物使用率高出25% (RR, 1.25;95% CI, 1.02 ~ 1.53;p = .03)。与男性相比,女性使用中枢神经系统(CNS)药物的比例高19% (RR, 1.19;95% CI, 1.03 ~ 1.37;P = .02),苯二氮卓类药物使用率高出30% (RR, 1.30;95%可信区间。1.09 ~ 1.54;P & lt;. 01)。高风险HCT-CI与任何pim的较高使用率相关(RR, 1.13;95% CI, 1.01 ~ 1.26;P = .02),中枢神经系统药物(RR, 1.26;95% CI, 1.04 ~ 1.53;P = .02)和GU用药(RR, 1.46;95% CI, 1.09 ~ 1.94;p = 0.01)。与匹配的兄弟姐妹供体HCT接受者相比,脐带血移植接受者的胃肠道药物使用率更高(RR, 1.32;95% CI, 1.14 ~ 1.53;P & lt;.01)和抗胆碱能药物使用(RR, 1.30;95% CI, 1.06 ~ 1.61;p = 0.01)。在≥65岁组中,增加麻醉药物使用时间与1.3倍相关(95% CI, 1.0至1.7;P = 0.05)总死亡率更高,CTCAE 3-4级毒性的发生率高1.6倍(95% CI, 1.02至2.69)(P = 0.04)。我们的数据显示,老年患者(≥65岁)接受pim的可能性与年轻患者相同。在老年接受者中,pim的使用,特别是麻醉品的使用,与更高的死亡率和更高的3-4级毒性发生率相关。确定并减少老年HCT受者的pim使用可能有助于减少不良事件的负担和相关的卫生保健费用。
{"title":"Use of Potentially Inappropriate Medications in Older Allogeneic Hematopoietic Cell Transplantation Recipients","authors":"Divya Bhargava ,&nbsp;Mukta Arora ,&nbsp;Todd E. DeFor ,&nbsp;Claudio G. Brunstein ,&nbsp;Bharat Thyagarajan ,&nbsp;Najla El Jurdi ,&nbsp;Shernan G. Holtan ,&nbsp;Armin Rashidi ,&nbsp;Erica Warlick ,&nbsp;Vidhyalakshmi Ramesh ,&nbsp;John Rogosheske ,&nbsp;Smita Bhatia ,&nbsp;Daniel J. Weisdorf","doi":"10.1016/j.bbmt.2020.08.031","DOIUrl":"10.1016/j.bbmt.2020.08.031","url":null,"abstract":"<div><p>The use of potentially inappropriate medications (PIMs) using Beers criteria and its impact on older allogeneic hematopoietic cell transplantation (HCT) recipients is not known. Here the use of any PIMs and their therapeutic classes in reduced-intensity conditioning allogeneic HCT recipients were compared between older (≥65 years; n = 114) and younger (40 to 64 years; n = 240) patients during their initial HCT admission, defined as the number of days that a patient received 1 or more PIMs between day -14 and day +28. Poisson regression was used to determine rate ratios (RRs) in the 2 groups. In the ≥65 years group, we evaluated the impact of PIMs on Common Terminology Criteria for Adverse Events (CTCAE) grade 3-4 toxicities within 100 days and on overall mortality within 1 year post-HCT. The rate of any PIM use was similar in the older and younger groups (RR, .98; 95% confidence interval [CI], .90 to 1.06; <em>P</em> = .65). In terms of PIM classes, the older group had a 48% higher rate of gastrointestinal (GI) medication use (RR, 1.48; 95% CI, 1.32 to 1.65; <em>P</em> &lt; .01) and a 25% higher rate of genitourinary (GU) medication use (RR, 1.25; 95% CI, 1.02 to 1.53; <em>P</em> = .03). Compared with males, females had a 19% higher rate of central nervous system (CNS) medication use (RR, 1.19; 95% CI, 1.03 to 1.37; <em>P</em> = .02) and a 30% higher rate of benzodiazepine use (RR, 1.30; 95% CI. 1.09 to 1.54; <em>P</em> &lt; .01). A high-risk HCT-CI was associated with a higher rate of use of any PIMs (RR, 1.13; 95% CI, 1.01 to 1.26; <em>P</em> = .02), CNS medications (RR, 1.26; 95% CI, 1.04 to 1.53; <em>P</em> = .02) and GU medications (RR, 1.46; 95% CI, 1.09 to 1.94; <em>P</em> = .01). Compared with matched sibling donor HCT recipients, umbilical cord blood transplantation recipients had higher rates of GI medication use (RR, 1.32; 95% CI, 1.14 to 1.53; <em>P</em> &lt; .01) and anticholinergic medication use (RR, 1.30; 95% CI, 1.06 to 1.61; <em>P</em> = .01). In the ≥65 years group, increasing duration of narcotic use was associated with a 1.3-fold (95% CI, 1.0 to 1.7; <em>P</em> = .05) higher risk of overall mortality and a 1.6-fold (95% CI, 1.02 to 2.69) greater odds of CTCAE grade 3-4 toxicities (<em>P</em> = .04). Our data show that older recipients (≥65 years) were as likely as their younger counterparts to receive PIMs. Among older recipients, the use of PIMs, particularly narcotics, was associated with higher mortality and higher incidence of grade 3-4 toxicities. Identifying and reducing the use of PIMs in older HCT recipients may help decrease the burden of adverse events and associated health care costs.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2329-2334"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38469946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Peritransplantation Use of Ruxolitinib in Myelofibrosis 鲁索利替尼在骨髓纤维化中的应用
IF 4.3 Q1 Medicine Pub Date : 2020-12-01 DOI: 10.1016/j.bbmt.2020.08.015
Uroosa Ibrahim, Giulia Eva Maria Petrone, John Mascarenhas, Alla Keyzner

Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.

Ruxolitinib是一种口服JAK1/2抑制剂,被批准用于中高风险骨髓纤维化(MF)患者,基于其已证实的脾脏和症状负担减轻。然而,它对造血干细胞移植(HSCT)结果的影响在很大程度上是未知的。大量进行HSCT的患者已经接受了ruxolitinib治疗,在已发表的文献中,ruxolitinib在移植周围使用的具体情况差异很大。在这里,我们回顾了目前发表的数据和经验,以指导MF患者在鲁索利替尼治疗下进行HSCT的管理。
{"title":"Peritransplantation Use of Ruxolitinib in Myelofibrosis","authors":"Uroosa Ibrahim,&nbsp;Giulia Eva Maria Petrone,&nbsp;John Mascarenhas,&nbsp;Alla Keyzner","doi":"10.1016/j.bbmt.2020.08.015","DOIUrl":"10.1016/j.bbmt.2020.08.015","url":null,"abstract":"<div><p>Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2177-2180"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38281571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Biology of Blood and Marrow Transplantation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1